Search clinical trials for: tremelimumab durvalumab

Total 783 results

AstraZeneca

Completed

Study of CP-675,206 in Refractory Melanoma

Refractory Melanoma

United States, Spain, Canada, France, Italy, United Kingdom, Argentina, Australia, Germany
AstraZeneca

Terminated

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Melanoma

United States
Emory University
AstraZeneca

Completed

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Recurrent Small Cell Lung Carcinoma

United States
MedPacto, Inc.
AstraZeneca

Not yet recruiting

Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Urothelial Carcinoma Recurrent | Advanced Urothelial Carcinoma

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Carcinoma, Non-Small-Cell Lung

United States, Australia
Monika Joshi, MD
AstraZeneca

Active, not recruiting

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (DUART)

Urothelial Cancer

United States
AstraZeneca

Completed

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-small-cell Lung

United States, Canada, Korea, Republic of, United Kingdom, Czech Republic
A.J.M. van den Eertwegh

Completed

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Cutaneous Melanoma
AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
Swiss Group for Clinical Cancer Research

Completed

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

NSCLC Non-small Cell Lung Cancer

Switzerland
Wuhan Union Hospital, China

Unknown

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Small Cell Lung Cancer | Anlotinib | Durvalumab
National University Hospital, Singapore

Unknown

A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

Ovarian Clear Cell Carcinoma

Singapore
AbbVie

Recruiting

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)

Hepatocellular Carcinoma

United States, Taiwan, Spain, France
University Health Network, Toronto

Terminated

Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients

Metastatic Breast Cancer

Canada
ETOP IBCSG Partners Foundation
AstraZeneca

Recruiting

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)

Non-small Cell Lung Cancer | Oligometastasis | Stage IV

Switzerland, Netherlands, Spain, Italy
MedImmune LLC

Withdrawn

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Microsatellite-stable Colorectal Cancer
Fujian Cancer Hospital

Enrolling by invitation

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Malignant Melanomas

China
Leo Mascarenhas

Completed

Durvalumab in Pediatric and Adolescent Patients

Lymphoma | Solid Tumor | Central Nervous System Tumors

United States
University of Colorado, Denver

Withdrawn

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Solid Tumor, Adult
University of Nebraska
AstraZeneca

Recruiting

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Lung Cancer | Carcinoma, Non-Small Cell Lung

United States
National Cancer Institute (NCI)

Terminated

Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma

Neoplasms | Mycosis Fungoides | Cutaneous T-Cell Lymphoma

United States
Tae Won Kim

Terminated

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Colorectal Cancer | Solid Tumor

Korea, Republic of
Celgene

Completed

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)

Multiple Myeloma

United States, Spain, Austria, Greece, Netherlands, Sweden
AHS Cancer Control Alberta

Completed

Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

Uveal Melanoma

Canada
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
Weill Medical College of Cornell University
AstraZeneca

Completed

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Innate Pharma
AstraZeneca

Terminated

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)

Advanced Solid Tumors

United States, France
Universität des Saarlandes

Recruiting

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Extensive-stage Small-cell Lung Cancer

Germany
Shanghai Chest Hospital

Active, not recruiting

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Extensive-Stage Small-Cell Lung Cancer

China
Nordic Society of Gynaecological Oncology - Clinical...
Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Recruiting

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (DOVACC)

Ovarian Cancer

Denmark
CCTU- Cancer Theme
Microbiotica Ltd

Recruiting

Microbiome Immunotherapy Toxicity and Response Evaluation

Melanoma | Lung Cancer | Renal Cancer

United Kingdom
F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
Radboud University Medical Center
AstraZeneca

Completed

Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer (Donan)

Non-small Cell Lung Cancer

Netherlands
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Thoraxklinik-Heidelberg gGmbH

Recruiting

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo)

NSCLC, Stage III

Germany
MedImmune LLC

Terminated

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Cancer | Solid Tumors | CTCL

United States, France, Canada
National Cancer Institute (NCI)

Completed

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Hepatocellular Carcinoma | Biliary Tract Neoplasms | Liver Cancer | Biliary Cancer | Heptocellular Cancer

United States
Sun Yat-sen University

Recruiting

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
University Medical Center Groningen

Not yet recruiting

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy (PREDICT)

Locally Advanced Rectal Carcinoma

Netherlands
University of Wisconsin, Madison
Pfizer

Withdrawn

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Bladder Cancer
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Anwaar Saeed
AstraZeneca; Exelixis

Active, not recruiting

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Adenocarcinoma

United States
Spanish Cooperative Group for the Treatment of...
AstraZeneca

Recruiting

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Metastatic Pancreatic Cancer

Spain
Elizabeth Dudnik

Recruiting

Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study

Patients With Advanced Treatment Naive LCNEC

Israel
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca

Recruiting

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA)

Early Small (cT1N0) Triple Negative Breast Cancer

France
University Hospital, Essen

Recruiting

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)

NSCLC, Stage III

Germany
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

Canada, Spain, United Kingdom
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC)

India
IRCCS Policlinico S. Matteo

Active, not recruiting

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Lung Cancer | Lung Cancer Stage III

Italy
Mario Negri Institute for Pharmacological Research

Completed

Diadem to Investigate the Activity and Safety of Durvalumab (Diadem)

Pleura Mesothelioma

Italy

Search clinical trials for: tremelimumab durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations